Physicians' Academy for Cardiovascular Education

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

In high Lp(a)-associated CV risk patients, reduction of Lp(a) with PCSK9 inhibition lowered this risk, even at very low LDL-c levels.


John Chapman is Research Professor at the Pierre and Marie Curie University, and Director Emeritus of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital in Paris, France.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: